# NMN vs NR: NAD+ Precursors Compared in the Research

> NMN vs NR compared: both are NAD+ precursors that raise blood NAD+. NR rose whole-blood NAD+ 22/51/142% at 100/300/1000 mg/day; NMN improved insulin sensitivity at 250 mg/day. Cited.

Two building blocks the body converts into NAD+ — what each is, the biochemical step that separates them, and what their human trials measured.

## In plain English

Comparing NMN vs NR is comparing two precursors — two building blocks the body converts into NAD+ (the fuel-handling helper molecule cells use to make energy). They matter because NAD+ itself absorbs poorly by mouth, so the products with real human evidence are precursors, not NAD+ [13]. The two sit at slightly different points on the same assembly line: NR is converted into NMN, and NMN is then converted into NAD+ [6]. Both reliably raised blood NAD+ in randomized trials. This page lays out what each is and what its studies showed; it recommends nothing.

## The shared biochemistry

NMN and NR feed the same destination by adjacent steps. In the salvage pathway, nicotinamide riboside is phosphorylated by NRK1/NRK2 kinases to become NMN, and NMN is then converted to NAD+ by NMNAT enzymes [6]. So NR sits one step upstream of NMN, and NMN sits one step from NAD+. Both routes are Preiss-Handler-independent and highly conserved from bacteria to humans [6].

The practical consequence is that both raise NAD+, and the choice between them in the literature is about which has the relevant *human* data for a given endpoint — not about one being NAD+ and the other not. Neither *is* NAD+; both are precursors [13]. The marketing tendency to conflate "NAD supplement," "NMN," "NR," and "NAD+" obscures exactly this point.

### Is taking NAD orally effective?

Plain oral NAD+ is poorly taken up intact, so most experts consider precursors the rational oral approach [13]. Oral NMN and NR reliably raise blood NAD+ in randomized trials [4][3], while translation to hard clinical endpoints is mixed [7].

## Nicotinamide mononucleotide (NMN)

Nicotinamide mononucleotide (NMN) is a direct NAD+ precursor sitting one biochemical step from NAD+ [6]. Its human evidence is among the most concrete in the field. A multicenter, double-blind, placebo-controlled, dose-ranging trial of NMN at 300, 600, and 900 mg/day for 60 days significantly raised blood NAD+ at days 30 and 60 across all groups (p≤0.001), improved walking distance and quality-of-life scores, identified 600 mg/day as optimal, and reported no safety issues at any dose [3]. In a separate trial, 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic, postmenopausal women, without changing body composition or HbA1c [8].

NMN carries one wrinkle the other precursor does not: a contested regulatory status. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug. This is a marketplace classification dispute, not a ban or a finding that NMN is illegal.

## Nicotinamide riboside (NR)

Nicotinamide riboside (NR) is the most clinically studied oral NAD+ precursor, converted to NMN by NRK kinases en route to NAD+ [6]. Its signature dataset is an 8-week, randomized, double-blind, placebo-controlled trial in healthy overweight adults: NR raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day respectively, dose-dependently and durably across the study [4]. Critically for a safety read, NR produced no flushing, did not elevate LDL cholesterol, did not disrupt one-carbon metabolism, and showed no significant adverse-event difference from placebo at any dose [4].

That trial is why NR is often described as a well-tolerated, dose-scalable NAD+ booster: the blood-NAD+ response is graded and predictable, and the tolerability profile in controlled testing was clean at the doses studied [4]. As with NMN, raising blood NAD+ is demonstrated; the harder clinical endpoints remain the open question across both precursors [7]. For the trials behind these figures, see [cited studies and references](/references).

---

A safety-first reel of the NAD+ literature — what the trials cut to, where the evidence drops off, and nothing dispensed, prescribed, or sold.